全文获取类型
收费全文 | 692篇 |
免费 | 50篇 |
出版年
2020年 | 6篇 |
2018年 | 12篇 |
2017年 | 6篇 |
2016年 | 9篇 |
2015年 | 25篇 |
2014年 | 14篇 |
2013年 | 27篇 |
2012年 | 30篇 |
2011年 | 34篇 |
2010年 | 22篇 |
2009年 | 22篇 |
2008年 | 26篇 |
2007年 | 25篇 |
2006年 | 24篇 |
2005年 | 29篇 |
2004年 | 25篇 |
2003年 | 19篇 |
2002年 | 26篇 |
2001年 | 16篇 |
2000年 | 12篇 |
1999年 | 22篇 |
1998年 | 16篇 |
1997年 | 15篇 |
1996年 | 7篇 |
1995年 | 8篇 |
1994年 | 12篇 |
1993年 | 9篇 |
1992年 | 18篇 |
1991年 | 6篇 |
1990年 | 11篇 |
1989年 | 14篇 |
1988年 | 12篇 |
1987年 | 15篇 |
1986年 | 18篇 |
1985年 | 9篇 |
1983年 | 5篇 |
1980年 | 8篇 |
1979年 | 11篇 |
1978年 | 10篇 |
1977年 | 4篇 |
1976年 | 7篇 |
1975年 | 10篇 |
1974年 | 7篇 |
1973年 | 5篇 |
1972年 | 7篇 |
1971年 | 7篇 |
1970年 | 16篇 |
1969年 | 10篇 |
1968年 | 10篇 |
1967年 | 4篇 |
排序方式: 共有742条查询结果,搜索用时 62 毫秒
71.
Masatomo Miura Satoru Motoyama Yudai Hinai Takenori Niioka Makoto Hayakari Jun‐Ichi Ogawa Toshio Suzuki 《Chirality》2010,22(7):635-640
The purpose of this study was to investigate whether CYP2C19 activity can be estimated from plasma concentrations of lansoprazole enantiomers 4 h (C4h) after single administration by oral and enteral routes. Sixty‐nine subjects, 22 homozygous extensive metabolizers (homEMs), 32 heterozygous EMs (hetEMs), and 15 poor metabolizers (PMs), participated in the study. After a single oral or enteral dose of racemic lansoprazole (30 mg), plasma concentrations of lansoprazole enantiomers were measured 4 h postdose. The R/S ratio of lansoprazole at 4 h differed significantly among the three groups (P < 0.0001) regardless of the administration route. The R/S ratio of lansoprazole in CYP2C19 PMs ranged from 3.0 to 13.7, whereas in homEMs and hetEMs the ratio ranged from 8.6 to 90 and 2.1 to 122, respectively. The relationship between (S)‐lansoprazole concentration and R/S ratio of lansoprazole at C4h is given by the following formula: log10 [R/S ratio] = 2.2 – 0.64 × log10 [C4h of (S)‐lansoprazole] (r = 0.867, P < 0.0001). Thus, phenotyping CYP2C19 using the R/S enantiomer ratio of lansoprazole seems unlikely. However, to obtain a pharmacological effect similar to that in CYP2C19 PMs, we can presume that lansoprazole has a sufficient effect in the patient with an R/S enantiomer ratio at 4 h ≤ 13.70 and (S)‐lansoprazole concentration at 4 h ≥ 50 ng/ml. Chirality 2010. © 2009 Wiley‐Liss, Inc. 相似文献
72.
Takashi Matozaki Yoji Murata Munemasa Mori Takenori Kotani Hideki Okazawa Hiroshi Ohnishi 《Cellular signalling》2010,22(12):1811-1817
The R3 subtype of receptor-type protein tyrosine phosphatases (RPTPs) includes VE-PTP, DEP-1, PTPRO, and SAP-1. All of these enzymes share a similar structure, with a single catalytic domain and putative tyrosine phosphorylation sites in the cytoplasmic region and fibronectin type III–like domains in the extracellular region. The expression of each R3 RPTP is largely restricted to a single or limited number of cell types, with VE-PTP and DEP-1 being expressed in endothelial or hematopoietic cells, PTPRO in neurons and in podocytes of the renal glomerulus, and SAP-1 in gastrointestinal epithelial cells. In addition, these RPTPs are localized specifically at the apical surface of polarized cells. The structure, expression, and localization of the R3 RPTPs suggest that they perform tissue-specific functions and that they might act through a common mechanism that includes activation of Src family kinases. In this review, we describe recent insights into R3-subtype RPTPs, particularly those of mammals. 相似文献
73.
Taisuke Matsuo Atsushi Yamamoto Takenori Yamamoto Kaoru Otsuki Naoshi Yamazaki Masatoshi Kataoka Hiroshi Terada Yasuo Shinohara 《Biochemical genetics》2010,48(3-4):193-201
Liver- and heart/muscle-type isozymes of human carnitine palmitoyltransferase I (L- and M-CPTI, respectively) show a certain similarity in their amino acid sequences, and mutation studies on the conserved amino acids between these two isozymes often show essentially the same effects on their enzymatic properties. Earlier mutation studies on C305 in human M-CPTI and its counterpart residue, C304, in human L-CPTI showed distinct effects of the mutations, especially in the aspect of enzyme stability; however, simple comparison of these effects on the conserved Cys residue between L- and M-CPTI was difficult, because these studies were carried out using different expression systems and distinct amino acids as replacements. In the present study, we carried out mutation studies on the C305 in human M-CPTI using COS cells for the expression system. Our results showed that C305 was replaceable with aspartic acid but that substitution with other amino acids caused both loss of function and reduced expression. 相似文献
74.
75.
76.
Hayakawa T Kanagawa R Kotani Y Kimura M Yamagiwa M Yamane Y Takebe S Sakai H 《Current microbiology》2007,55(4):278-283
A novel crystal protein that exhibited potent cytotoxicity against human leukemic T-cells was cloned from the Bacillus thuringiensis TK-E6 strain. The protein, designated as parasporin-2Ab (PS2Ab), was a polypeptide of 304 amino acid residues with a predicted
molecular weight of 33,017. The deduced amino acid sequence of PS2Ab showed significant homology (84% identitiy) to parasporin-2Aa
(PS2Aa) from the B. thuringiensis A1547 strain. Upon processing of PS2Ab with proteinase K, the active form of 29 kDa was produced. The activated PS2Ab showed
potent cytotoxicity against MOLT-4 and Jurkat cells and the EC50 values were estimated as 0.545 and 0.745 ng/mL, respectively. The cytotoxicity of PS2Ab was significantly higher than that
of PS2Aa reported elsewhere. Although both cytotoxins were structurally related, it was thought that the minor differences
found were responsible for the different cytotoxicities of PS2Ab and PS2Aa. 相似文献
77.
Kojima H Suzuki T Kato T Enomoto K Sato S Kato T Tabata S Sáez-Vasquez J Echeverría M Nakagawa T Ishiguro S Nakamura K 《The Plant journal : for cell and molecular biology》2007,49(6):1053-1063
Animal and yeast nucleolin function as global regulators of ribosome synthesis, and their expression is tightly linked to cell proliferation. Although Arabidopsis contains two genes for nucleolin, AtNuc-L1 is the predominant if not only form of the protein found in most tissues, and GFP-AtNuc-L1 fusion proteins were targeted to the nucleolus. Expression of AtNuc-L1 was strongly induced by sucrose or glucose but not by non-metabolizable mannitol or 2-deoxyglucose. Sucrose also caused enhanced expression of genes for subunits of C/D and H/ACA small nucleolar ribonucleoproteins, as well as a large number of genes for ribosomal proteins (RPs), suggesting that carbohydrate availability regulates de novo ribosome synthesis. In sugar-starved cells, induction of AtNuc-L1 occurred with 10 mM glucose, which seemed to be a prerequisite for resumption of growth. Disruption of AtNuc-L1 caused an increased steady-state level of pre-rRNA relative to mature 25S rRNA, and resulted in various phenotypes that overlap those reported for several RP gene mutants, including a reduced growth rate, prolonged lifetime, bushy growth, pointed leaf, and defective vascular patterns and pod development. These results suggest that the rate of ribosome synthesis in the meristem has a strong impact not only on the growth but also the structure of plants. The AtNuc-L1 disruptant exhibited significantly reduced sugar-induced expression of RP genes, suggesting that AtNuc-L1 is involved in the sugar-inducible expression of RP genes. 相似文献
78.
79.
80.
Yoshida M Mori A Morimoto S Kotani E Oka M Notoya K Makino H Ono M Shirasaki M Tada N Fujita H Ban J Ikeda Y Kawamoto T Goto M Kimura H Baba A Yasuma T 《Bioorganic & medicinal chemistry》2011,19(6):1881-1894
The calcium-sensing receptor antagonist (CaSR) has been recognized as a promising target of anabolic agents for treating osteoporosis. In the course of developing a new drug candidate for osteoporosis, we found tetrahydropyrazolopyrimidine derivative 1 to be an orally active CaSR antagonist that stimulated transient PTH secretion in rats. However, compound 1 showed poor physical and chemical stability. In order to work out this compound's chemical stability and further understand its in vivo efficacy, we focused on modifying the 2-position of the tetrahydropyrazolopyrimidine. As a result of chemical modification, we discovered (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate 10m (TAK-075), which showed improved solubility, chemical stability, and in vivo efficacy. Furthermore, we describe that evaluating the active metabolite is important during repeated treatment with short-acting CaSR antagonists. 相似文献